Clinical Trials Logo

High Risk clinical trials

View clinical trials related to High Risk.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06409702 Not yet recruiting - Multiple Myeloma Clinical Trials

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Start date: May 2024
Phase:
Study type: Observational

The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction & consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients. It aims to evaluate the efficacy and safety of the combination regimen of Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (DKRD) +/- ASCT for the treatment of patients with newly diagnosed high-risk multiple myeloma. Participants will receive bortezomib based induction therapy for one cycle, and then DKRD induction for 3 cycles(+ASCT), DKRD consolidation for 2-4 cycles, and DKR maintenance treatment(adjusted according to MRD negativity after consolidation therapy)

NCT ID: NCT05778097 Not yet recruiting - Prostate Cancer Clinical Trials

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

ARES
Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.

NCT ID: NCT05566587 Not yet recruiting - Diet, Healthy Clinical Trials

Designing a Personalized Diet to Reduce the Risk of Crohn's Disease Onset

Start date: October 2022
Phase: N/A
Study type: Interventional

The purpose of this trial is to run a pilot study that examines the impact of different dietary components on risk factors such as the Genetic, Environmental, Microbial (GEM) Microbiome Risk Score (GMRS) and fecal calprotectin (FCP), a marker of inflammation in the bowels, and a risk factor for developing Crohn's disease (CD) among first degree relatives (parents, siblings, or offspring) of Crohn's patients. The study will utilize the Western diet and the Mediterranean diet to explore the complex interplay between diet, microbiome, and inflammatory biomarkers to identify specific dietary components that may be beneficial in reducing the risk of developing CD. The study will enroll 30 participants from Mount Sinai Hospital in Toronto.